

1 Charles S. LiMandri, SBN 110841  
cslimandri@limandri.com  
2 Paul M. Jonna, SBN 265389  
pjonna@limandri.com  
3 Jeffrey M. Trissell, SBN 292480  
jtrissell@limandri.com  
4 Brian M. McPherson, SBN 345196  
bmcpherson@limandri.com  
5 LiMANDRI & JONNA LLP  
6 P.O. Box 9120  
7 Rancho Santa Fe, CA 92067  
Telephone: (858) 759-9930  
8 Facsimile: (858) 759-9938

9 Peter Breen, *pro hac vice*  
pbreen@thomasmoresociety.org  
10 THOMAS MORE SOCIETY  
11 121 West Wacker Drive, Ste. 650  
Chicago, IL 60601  
12 Tel: (312) 782-1680

13 *Attorneys for Defendants Heartbeat*  
14 *International, Inc. & RealOptions, Inc.*

Andrew S. Hollins, SBN 80194  
ahollins@messner.com  
Ethan A. Reimers, SBN 311020  
ereimers@messner.com  
MESSNER REEVES LLP  
650 Town Center Drive, Suite 700  
Costa Mesa, CA 92626  
Telephone: (949) 612-9128  
Facsimile: (310) 889-0896

*Attorneys for Defendant RealOptions, Inc.*

15 SUPERIOR COURT OF THE STATE OF CALIFORNIA

16 COUNTY OF ALAMEDA

17 THE PEOPLE OF THE STATE OF  
18 CALIFORNIA,

19 Plaintiff,

20 v.

21 HEARTBEAT INTERNATIONAL, INC.,  
22 AND REALOPTIONS, INC.,

23 Defendants.

Case No.: 23CV044940

**DEFENDANTS' TRIAL BRIEF**

Judge: Hon. Patrick McKinney

Dept: 18

Date: June 24, 2026

Time: 10:00 a.m.

Action filed: September 21, 2023

**TABLE OF CONTENTS**

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

I. INTRODUCTION..... 1

II. SUMMARY OF LEGAL ISSUES..... 1

    A. First Threshold Issue: Defendants’ Speech About APR is Not Commercial..... 1

    B. Second Threshold Issue: The AG’s Failure-to-Substantiate Theory Is Invalid. .... 2

    C. The AG Fails to Show Defendants’ Speech is False or Misleading Advertising. ...3

        1. Elements of an FAL/UCL Claim. ....3

        2. The Attorney General Cannot Satisfy the Elements..... 4

            a. Heartbeat’s APR Referral Program. .... 4

            b. RealOptions’s APR Treatment. ....5

            c. Heartbeat’s APR Advocacy..... 6

    D. Defendants’ APR Speech is Constitutionally Protected. .... 6

        1. Free Speech..... 6

            a. The AG targets matters of disputed science based on content..... 6

            b. Viewpoint-based restriction..... 8

            c. The AG Cannot Satisfy Even Intermediate Scrutiny. .... 8

        2. Free Exercise of Religion..... 9

        3. Reproductive Privacy rights..... 9

    E. Any Penalties Should Be De Minimis..... 10

III. CONCLUSION..... 10

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20

## I. INTRODUCTION

This case asks if truthful statements about a free service are punishable commercial fraud. Defendants Heartbeat International, Inc. and RealOptions, Inc. are religiously motivated pro-life charities. They provide free information about supplemental progesterone—“Abortion Pill Reversal” or “APR”—to women who have begun a chemical abortion but seek to preserve their pregnancies. The Attorney General alleges in this enforcement action that several of their APR statements are false or misleading commercial speech under the False Advertising Law (FAL) and Unfair Competition Law (UCL), which are fined at \$2,500 under each statute (\$5,000 total). He alleges 128 violations by RealOptions, which totals \$640,000 in fines and 3,972 violations by Heartbeat or \$19.86 million in fines. Beyond crippling fines, the Attorney General seeks injunctive relief to prevent Defendants from communicating scientific findings about a legal, safe, and effective medical procedure.

The record does not support that extraordinary relief for numerous reasons. Defendants’ speech is not false or misleading, but supported by the FDA and numerous peer-reviewed journal articles. Even if it were false, it is protected by a litany of constitutional rights such that Defendants’ speech alone could only be restricted if it caused real harm. Yet, despite pre-litigation investigations and extensive discovery, the Attorney General has never been able to find any harm—only happy mothers. And even if Defendants’ speech did violate the FAL and UCL, \$20 million in fines would be a clearly exorbitant and vindictive penalty for offering a free service for which nobody has ever been harmed or complained, and would force local nonprofits serving their communities into bankruptcy.

## II. SUMMARY OF LEGAL ISSUES

### A. First Threshold Issue: Defendants’ Speech About APR is Not Commercial.

21  
22  
23  
24  
25  
26  
27  
28

The AG concedes that the FAL and UCL reach only commercial speech. (AG Resp. to RFA Nos. 12, 13.) Commercial speech “does no more than propose a commercial transaction.” (*Bernardo v. Planned Parenthood Fedn. of America* (2004) 115 Cal.App.4th 322, 343, quotations omitted). The applicable factors are whether the speaker is commercial, the intended audience is commercial, and the speech contains “representations of fact of a commercial nature.” (*Kasky v. Nike, Inc.* (2002) 27 Cal.4th 939, 963-964, citations omitted.) For close calls, courts also consider whether an economic motive is the *primary* driver for the speech. (*Id.* at pp.956-957; *Ariix, LLC v. NutriSearch Corp.* (9th Cir. 2021) 985

1 F.3d 1107, 1117.) And speech loses any commercial character if “inextricably intertwined with otherwise  
2 fully protected speech” (*Riley v. Natl. Fedn. of the Blind* (1988) 487 U.S. 781, 796), or about matters of  
3 the “highest public interest and concern.” (*Pines v. Tomson* (1984) 160 Cal.App.3d 370, 392-393.)

4 Defendants’ APR speech is not commercial under those standards. They are noncommercial  
5 entities, direct their APR statements to a noncommercial audience of women facing an abortion decision  
6 and a broader audience of supporters and the general public, and provide free information. Their speech  
7 is driven by sincere religious, rather than economic, motives. And the speech falls squarely within a  
8 “rancorous national controversy” about abortion. (*Dobbs v. Jackson Women’s Health Org.* (2022) 597  
9 U.S. 215, 292.) None of this is “expression related solely to the economic interests of the speaker and  
10 its audience.” (*Central Hudson Gas & Elec. Corp. v. Public Service Com.* (1980) 447 U.S. 557, 561.)

11 The Attorney General’s sole argument is that Defendants’ fundraising changes the analysis.  
12 (See *First Resort, Inc. v. Herrara* (9th Cir. 2017) 860 F.3d 1263, abrogated by *NIFLA v. Becerra* (2018)  
13 585 U.S. 755.) It does not. It is “incidental and collateral to their main object” of helping women and  
14 their unborn children. (*Murdock v. Pennsylvania* (1943) 319 U.S. 105, 111-1112; *Ariix, supra*, 985 F.3d at  
15 p.1117 & fn.7.) It is equally irrelevant that donations “may rise” when a nonprofit communicates its  
16 “victories” to supporters. (*In re Primus* (1978) 436 U.S. 412, 429-430.)<sup>1</sup> That conclusion does not  
17 change just because speech concerns a medical service, least of all in this case, where Heartbeat “do[es]  
18 not provide APR” itself and RealOptions does not provide APR “in order to gain some financial  
19 benefit,” as it “receive[s] no direct or indirect payment” for the APR it provides. (*NIFLA v. James* (2d  
20 Cir. 2025) 160 F.4th 360, 376-77.)

21 **B. Second Threshold Issue: The AG’s Failure-to-Substantiate Theory Is Invalid.**

22 Although government “prosecuting authorities ... may demand advertisers substantiate their  
23 claims *before* pursuing an action,” “[a]t trial” a prosecutor “still bears the burden of proving that the  
24 representations are false or misleading.” (*Mullins v. Premier Nutrition Corp.* (N.D. Cal. 2016) 178  
25 F.Supp.3d 867, 892; citing *Natl. Council Against Health Fraud, Inc. v. King Bio Pharmaceuticals, Inc.*  
26 (2003) 107 Cal.App.4th 1336, 1348, emphases added.) A prosecuting authority may not “shift the  
27 burden to the defendant to substantiate its claims” i.e., prove the “tru[th]” of their advertising claims.

28 <sup>1</sup> The same is true of Heartbeat’s membership fees and incidental program revenue, which it receives  
for the purpose of supporting its noncommercial, religiously motivated mission.

1 (*Id.* at p.1347.) He instead must prove falsity or misleadingness “by testing, scientific literature, or  
2 anecdotal evidence.” (*Id.* at pp.892-893; citing *King Bio, supra*, 107 Cal.App.4th at 1348.)<sup>2</sup>

3 The Attorney General fails to carry that burden. His only “evidence” is testimony criticizing  
4 Defendants’ “testing, scientific literature, or anecdotal evidence” in support of APR. (*King Bio, supra*,  
5 at p.1348.) He points to no studies whatsoever even purporting to show APR is not safe or effective.  
6 The only affirmative study he cites is Creinin 2020, but only for the (specious) proposition that it  
7 “suggests—but does not establish—that bleeding requiring medical intervention is a potential side  
8 effect of” mifepristone without misoprostol. (AG’s Resp. to FROGs, pg. 27). Notably, even the FDA  
9 prohibits drug label warnings absent “significant medical evidence of a possible health hazard,”  
10 including “when differences of opinion exist within the medical community with regard to potential  
11 adverse reactions.” (*Carlin v. Superior Court* (1996) 13 Cal.4th 1104, 1114.)<sup>3</sup> The Attorney General’s  
12 reliance on mere criticisms of Defendants’ affirmative evidence *per se* fails to meet his burden.

13 **C. The AG Fails to Show Defendants’ Speech is False or Misleading Advertising.**

14 **1. Elements of an FAL/UCL Claim.**

15 The Attorney General’s UCL claim is derivative of his FAL claim, so the claims overlap here.  
16 (*Kasky v. Nike, Inc.* (2002) 27 Cal.4th 939, 950-951.) The FAL prohibits anyone (1) “with intent directly  
17 or indirectly to dispose of real or personal property or to perform services ... to induce the public to  
18 enter into any obligation relating thereto,” (2) “to make or disseminate ... before the public ... any  
19 statement, concerning that ... property or those services ... which is untrue or misleading,” and  
20 (3) which is known, or which by the exercise of reasonable care should be known, to be untrue or  
21 misleading.” (Bus. & Prof. Code, § 17500.)

22 The second element requires proof that a *significant portion* of the public or targeted consumers  
23 who are acting reasonably under the circumstances is *likely* to be deceived when a statement is read in  
24

---

25 <sup>2</sup> This is distinct from the FTC, which can prevail either by “carry[ing] the burden of proving that  
26 the express or implied message by the ad is false,” or “[a]lternatively” by “show[ing] that the  
27 advertiser lacked a reasonable basis for asserting that the message was true.” (*FTC v. Garvey* (9th  
28 Cir. 2004) 383 F.3d 891, 901.) Critically, unlike California law, a “reasonable basis” claim “*does not*  
require the FTC to prove that the message was false in order to prevail.” (*Id.*, emphasis added)

<sup>3</sup> This position is also inconsistent as the Attorney General insists that Defendants’ statements  
regarding the efficacy of APR are invalid insofar as they rely on *case series* that allegedly only *suggest*  
rather than “*establish*” facts about APR.

1 context. (*Bank of the West v. Sup. Ct.* (1992) 2 Cal.4th 1254, 1267; *Lavie v. Procter & Gamble Co.* (2003)  
2 105 Cal.App.4th 496, 508-510; *Salazar v. Walmart, Inc.* (2022) 83 Cal.App.5th 561, 566, 569.) Similarly,  
3 only a “material” misrepresentation is actionable, that is, when “a reasonable man would attach  
4 importance to its existence or nonexistence in determining his choice of action in the transaction in  
5 question.” (*Fairbanks v. Farmers New World Life Ins. Co.* (2011) 197 Cal.App.4th 544, 565.) The third  
6 element requires intentional or at least negligent misrepresentation. (*Khan v. Medical Bd.* (1993) 12  
7 Cal.App.4th 1834, 1846; *People v. Forest E. Olson, Inc.* (1982) 137 Cal.App.3d 137, 140.)

## 8                   2.       **The Attorney General Cannot Satisfy the Elements.**

### 9                   a.       **Heartbeat’s APR Referral Program.**

10           The Attorney General targets several statements (and an alleged omission) within Heartbeat’s  
11 APR referral program. None are actionable.

12           **(i) “Reversal.”** Established science confirms that an *agonist* (i.e., supplemental progesterone)  
13 can outcompete an *antagonist* with a stronger binding affinity (i.e., mifepristone) at a receptor they both  
14 can bind to if the agonist concentration is high enough. (Accord *Bella Health & Wellness v. Weiser* (D.  
15 Colo. 2025) 793 F. Supp. 1320, 1332.) That is accepted science. “Reverse” accurately describes this  
16 “competitive inhibition” process. When the vast weight of evidence is on Defendants’ side, their  
17 statements cannot be false (as opposed to opinion). (*Bernardo, supra*, 115 Cal.App.4th at pp.348-349.)

18           **(ii) “Effective.”** Defendants have abundant, valid, peer-reviewed scientific support for  
19 describing APR as effective. That evidence base includes the 2018 Delgado study, 2012 Delgado study,  
20 the DeBeasi Report, the 2017 Garratt and Turner study, the 2023 Turner study, and the UC Davis  
21 study—alongside FDA reviews, and standard biochemistry, which is all backed up by both Heartbeat’s  
22 and RealOptions’ internal data. That evidence shows an almost 0% likelihood of this success being due  
23 to chance and, at minimum, Defendants have acted with reasonable care (i.e., not negligently) in relying  
24 on this body of science when speaking about APR’s effectiveness.

25           **(iii) 64%-68% success rate & birth-defects.** These statements accurately reflect the 2018  
26 Delgado study findings as to oral and intramuscular APR and birth-defect observation. The vast  
27 majority of APR is administered orally. Defendants even caveat that the rate is only from “initial  
28 studies.” The Attorney General’s primary criticism is that the study itself was not “credible,” but

1 Delgado 2018 is eminently credible and reliable and Defendants’ reliance on it was not negligent.

2           **(iv) APR “May” Work After 72 Hours.** Defendants advise women that it may not be too late  
3 to save their pregnancy even if 72 hours have passed since taking mifepristone. The Attorney General’s  
4 primary criticism is that there is no study reviewing these cases, although numerous individual cases do  
5 exist. But in light of the conditional nature of the advisement, the Attorney General must prove that it  
6 could never work, which he can’t. As discussed, the basic science of APR shows that it can outcompete  
7 otherwise active mifepristone and individual cases have been documented.

8           **(v) Misoprostol/Methotrexate.** Defendants advise women that progesterone “may” help  
9 support their “pregnancy” after taking misoprostol or methotrexate, even though it is “not an  
10 antidote.” Like above, the Attorney General’s primary criticism is that there is no study reviewing these  
11 cases, although numerous individual cases of APR after misoprostol or methotrexate do exist.<sup>4</sup> But  
12 Defendants make numerous disclaimers that there are no such studies, but that a woman can still  
13 request a referral if she wants, which is sufficient. (*A&M Produce Co. v. FMC Corp.* (1982) 135  
14 Cal.App.3d 473, 490.)<sup>5</sup>

15           **(vi) “Severe, life-threatening bleeding.”** The Attorney General demands that Defendants  
16 disclose that APR can supposedly cause “severe, life-threatening bleeding.” But that demand is based  
17 solely on the failed 2020 Creinin study. (AG’s Resp. to FROGs, pg. 27.) Again, even the FDA would  
18 not allow disclosure on such flimsy “evidence.” (*Carlin, supra*, 13 Cal.4th at p.1114.) And the records in  
19 Creinin’s failed study showed that his conclusion was absolutely false. No women in the APR group had  
20 a hemorrhage requiring medical intervention.

21                           **b. RealOptions’s APR Treatment.**

22           **(i) Website.** The Attorney General challenges RealOptions’ use on its website of Heartbeat’s  
23 model FAQs, which include references to APR being (i) “reversal,” (ii) “effective,” and (iii) having a  
24 64-68% success rate in initial studies. This speech is not false or misleading for the reasons stated above.

25           **(ii) Informed Consent Forms.** The Attorney General also alleges that RealOptions’ informed  
26

---

27 <sup>4</sup> Heartbeat has never provided a methotrexate referral to a California woman.

28 <sup>5</sup> The same disclosures are conspicuously provided on the second page of Heartbeat’s model consent forms and meant to be read *before* the woman has consented to any APR treatment. They are hardly akin to the Attorney General’s later-disclosure and fine-print case citations.

1 consent form is misleading for failing to disclose APR’s supposed life-threatening side-effect. But, as  
2 stated above, there is no evidence whatsoever to support that APR can be dangerous.

3 **c. Heartbeat’s APR Advocacy.**

4 The Attorney General targets APR information on Heartbeat’s supporter-facing APR page, and  
5 as presented by Heartbeat personnel on two podcasts. But these statements are all aimed at current or  
6 potential supporters, seeking to spread the word about APR. Communication to prospective and current  
7 donors is quintessentially non-commercial (*Kasky, supra*, 27 Cal.4th at pp.966-967), and thus not  
8 subject to the FAL and UCL in this action.

9 Even assuming these statutes apply, the Attorney General’s claims largely fail on the merits for  
10 the reasons just discussed (i.e., “reversal” and “effective” are accurate characterizations). Additionally,  
11 the Attorney General targets statements announcing that “*statistics* show thousands of lives” have been  
12 saved. That statement is derivative of others (i.e., the “effective” statement) but also accurately reflects  
13 an aggregation of APR data, which is a valid *statistical* measure, and which includes a baseline of 1,545  
14 *known* mifepristone reversals.

15 **D. Defendants’ APR Speech is Constitutionally Protected.**

16 **1. Free Speech**

17 Defendants’ speech is protected even assuming, *arguendo*, it is commercial. The U.S. Supreme  
18 Court cautions that “[f]alse commercial speech ... has never been listed among the historically  
19 unprotected categories of speech.” (*Counterman v. Colorado* (2023) 600 U.S. 66, 77, fn.4.) And  
20 commercial speech that is only “*potentially* misleading” still triggers intermediate scrutiny. (*American*  
21 *Academy, supra*, 353 F.3d at p.1107.) Defendants’ APR information is protected speech.

22 **a. The AG targets matters of disputed science based on content.**

23 “[S]tatements about contested” science receive special constitutional protection because they  
24 resemble opinion: “the conclusions of empirical research are tentative and subject to revision.” (*ONY,*  
25 *Inc. v. Cornerstone Therapeutics, Inc.* (2d Cir. 2013) 720 F.3d 490, 496-498.) That principle has particular  
26 force in medicine, and earlier this year the U.S. Supreme Court reaffirmed that content-based  
27 censorship even of for-profit medical speech based on alleged “medical consensus” triggers strict  
28 scrutiny, because “medical consensus” “evolves” and “[l]icensed professionals have a host of good-

1 faith disagreements about the prudence and ethics of various practices in their field.” (*Chiles v. Salazar*  
2 (2026) 146 S.Ct. 1010, 1029, quotations omitted.)

3 That aptly describes this case. The Attorney General seeks to punish, based on content, speech  
4 that accurately recites findings of valid peer-reviewed scientific studies amidst (at worst) a “good-faith  
5 disagreement” among “licensed professionals” about APR. He highlights professionals he claims agree  
6 with him about APR while ignoring conclusions of professional obstetrics associations with collectively  
7 more than ten thousand members that endorse APR, such as AAPLOG. While the Attorney General  
8 has a right to agree with one side of the scientific debate and publish his view that that side is correct,  
9 he may not impose crippling penalties to silence Defendants for agreeing with the other side of this live  
10 and good-faith debate among obstetrics professionals.

11 The Attorney General also lacks proof of cognizable “injury,” which would ensure “breathing  
12 room for protected speech.” (*Chiles, supra*, 146 S.Ct. at p.1029.) Thus, he is attempting to censor alleged  
13 “falsity alone,” disassociated from any “legally cognizable harm.” (*U.S. v. Alvarez* (2012) 567 U.S. 709,  
14 719 [plur. opn.]; accord *id.* at pp.730-731 [conc. opn. of Breyer, J.]<sup>6</sup> Indeed, he *admits* he has “no  
15 evidence of any complaints from APR patients related to APR treatment.” (AG Resp. to RFA Nos. 4,  
16 17; AG Resp. to FROG No. 3.) Nor can he show that Defendants spoke with the mens rea the First  
17 Amendment requires when government suppresses potentially protected speech based on content.  
18 (*Counterman, supra*, 600 U.S. at p.75.) The same applies to allegedly commercial speech. (*Sorrell v. IMS*  
19 *Health, Inc.* (2011) 564 U.S. 552, 566, 577.)

20 *Zauderer* also limits the Attorney General’s theory. To be sure, government may restrict false  
21 commercial speech under certain circumstances. (*Zauderer v. Office of Disciplinary Counsel* (1985) 471  
22 U.S. 626.) But *Zauderer* allows only *disclaimers* that are “purely factual” and “noncontroversial.”  
23 Abortion-related information is “anything but ... ‘uncontroversial.’” (*NIFLA v. Becerra* (2018) 585 U.S.  
24 755, 768.) The same goes for legitimately disputed science. (*California Chamber of Commerce v. Council*  
25 *for Educ. & Research. on Toxics* (9th Cir. 2022) 29 F.4th 468, 478 [disclosure wrongly “elevates one side  
26 of a legitimacy unresolved scientific debate”].)

27 \_\_\_\_\_  
28 <sup>6</sup> Nothing in *Alvarez*’s condemnation of censorship of alleged “falsity alone” *excludes* commercial  
speech. (See *Kohls v. Bonta* (E.D. Cal. 2025) 797 F.Supp.3d 1177, 1184 [statute unconstitutional  
because “unlike fraud, AB 2839 does not require reliance or actual injury”].)





1 including by interfering with Defendants’ attempts to *aid or assist* pregnant women in exercising their  
2 right to continue a wanted pregnancy. (Health & Saf. Code, § 1123467(b).) The Attorney General’s  
3 enforcement action thus triggers strict scrutiny for this reason, too, which he makes no attempt to meet.

4 **E. Any Penalties Should Be De Minimis.**

5 In light of the above, Defendants have not violated the FAL or UCL and no remedy is needed.  
6 Nevertheless, for completeness, Defendants offer a brief overview of the relevant considerations. Under  
7 the FAL, a violation is punished “by a fine not exceeding two thousand five hundred dollars  
8 (\$2,500).” (Bus. & Prof. Code, § 17500.) The same is true for the UCL. (Bus. & Prof. Code, § 17206,  
9 subd. (a).) The Court can order a duplicative penalty if the same conduct violates both statutes.  
10 (*People v. Johnson & Johnson* (2022) 77 Cal.App.5th 295, 318.) The statutes of limitations for the FAL  
11 is three years, such that violations which occurred prior to September 21, 2020 could not be  
12 penalized. (Bus. & Prof. Code, § 17536; Code Civ. Proc., § 338(h).) The FAL also does not apply  
13 extraterritorially, so Heartbeat cannot be penalized for out-of-state referrals. (*Planned Parenthood*  
14 *Fedn. of America, Inc. v. Center for Medical Progress* (N.D. Cal. 2020) 613 F.Supp.3d 1190, 1214.)

15 Under the FAL, “the duty to impose a penalty for each violation ... is mandatory.” (*People v.*  
16 *Custom Craft Carpets, Inc.* (1984) 159 Cal.App.3d 676, 686.) “The amount of each penalty, however,  
17 lies within the court’s discretion.” (*Id.*) More, the number of violations could be calculated on  
18 multiple bases, including a per victim basis or a per day basis. (*People v. Overstock.com, Inc.* (2017) 12  
19 Cal.App.5th 1064, 1088.) The amount of the penalty is based on the seriousness of the misconduct,  
20 its willfulness, the number of violations, and the defendant’s assets. (Bus. & Prof. Code, § 17206,  
21 subd. (b).) Thus, relevant is “the amount of the [defendant’s] monetary gain.” (*People v. Natl. Assn.*  
22 *of Realtors* (1984) 155 Cal.App.3d 578, 586.) Here, there is no FAL violation. But even if there were,  
23 because Defendants’ APR speech is entirely charitable, and religiously motivated, with no monetary  
24 gain and nobody ever harmed, any penalty would need to be de minimis.<sup>8</sup>

25 **III. CONCLUSION**

26 This Court should find Defendants not liable.


---

27 <sup>8</sup> (See *People v. Beaumont Investment, Ltd.* (2003) 111 Cal.App.4th 102 [\$37 each for 14,124 violations:  
28 \$525,000 penalty]; *People v. Morse* (1993) 21 Cal.App.4th 259 [\$0.10 each for 4 million violations:  
\$400,000 penalty]; *People v. Dollar Rent-A-Car Systems, Inc.* (1989) 211 Cal.App.3d 119 [\$0.20 each  
for 500,000 violations: \$100,000 penalty].)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

Respectfully submitted,  
LiMANDRI & JONNA LLP

Dated: June 10, 2026

By:   
\_\_\_\_\_  
Charles S. LiMandri  
Paul M. Jonna  
Jeffrey M. Trissell  
Brian M. McPherson  
Attorneys for Defendants Heartbeat  
International, Inc. and RealOptions, Inc.

COURT OF THE STATE OF CALIFORNIA ALAMEDA COUNTY SUPERIOR COURT - OAKLAND BRANCH		FOR COURT USE ONLY
TITLE OF CASE (Abbreviated) <b>People of the State of California v. Heartbeat Int'l, Inc., et al.</b>		
ATTORNEY(S) NAME AND ADDRESS Charles S. LiMandri, Esq.; Paul M. Jonna, Esq. Jeffrey M. Trissell, Esq., Esq. LiMANDRI & JONNA LLP P.O. Box 9120 Rancho Santa Fe, California 92067 Tele: (858) 759-9930; Fax: (858) 759-9938		
ATTORNEY(S) FOR: Defendants Heartbeat International, Inc. and RealOptions, Inc.	Dept. 18	CASE NO.: 23CV044940 JUDGE: Hon. Michael Markman

**CERTIFICATE OF SERVICE**

I, Kathy Denworth, declare that: I am over the age of 18 years and not a party to the action; I am employed in, or am a resident of the County of San Diego, California; where the mailing occurs; and my business address is P.O. Box 9120, Rancho Santa Fe, CA 92067, Telephone number (858) 759-9930; Facsimile number (858) 759-9938. I further declare that I served the following document(s) on the parties in this action:

- DEFENDANTS' TRIAL BRIEF.**

by one or more of the following methods of service to:

Rob Bonta, Attorney General of California  
Renu George, Senior Assistant Attorney General  
Karli Eisenberg, Supervising Deputy Attorney General  
Kathleen Boergers, Supervising Deputy Attorney General  
Erica Connolly, Deputy Attorney General  
Hayley Penan, Deputy Attorney General  
Lauren Zweier, Deputy Attorney General  
1300 "I" Street, Suite 125  
P.O. Box 944255  
Sacramento, CA 94244-2550  
Tel: (916) 210-7755; Fax: (916) 327-2319  
E-Mail: Erica.Connolly@doj.ca.gov  
E-Mail: karli.eisenberg@doj.ca.gov  
E-Mail: kathleen.boergers@doj.ca.gov  
E-Mail: hayley.penan@doj.ca.gov  
E-Mail: lauren.zweier@doj.ca.gov  
E-Mail: Andy.Marquez@doj.ca.gov  
E-Mail: cheryll.tran@doj.ca.gov  
**Attorney for Plaintiffs The People of the State of California**


Andrew S. Hollins, Esq.  
Ethan Reimers, Esq.  
Messner Reeves LLP  
611 Anton Blvd., Ste. 450  
Costa Mesa, CA 92626  
Tel: 949-612-9128; Fax: 949-438-2304  
E-Mail: ahollins@messner.com  
E-Mail: ereimers@messner.com  
E-Mail: sjohnson@messner.com  
**Attorneys for Defendant Real Option, Inc.**

Peter Breen, Esq.  
Thomas Brejcha, Esq.  
Michael McHale, Esq.  
Christopher Galiardo, Esq.  
THOMAS MORE SOCIETY  
309 West Washington, Ste. 1250  
Chicago, IL 60606  
Tel: (312) 782-1680  
E-Mail: pbreen@thomasmoresociety.org  
E-Mail: mmchale@thomasmoresociety.org  
E-Mail: cgaliardo@thomasmoresociety.org

X  **(BY E-MAIL/ELECTRONIC MAIL)** I caused a copy of the foregoing document(s) to be sent to the persons at the e-mail addresses listed above, this date via internet/electronic mail.

X  **(BY ELECTRONIC FILING/SERVICE)** I caused such document(s) to be Electronically Filed and/or Service through the One Legal System.

I declare under penalty of perjury under the laws of the State of California that the foregoing is true and correct. Executed on June 10, 2026.

  
\_\_\_\_\_  
Kathy Denworth